TMN355

Cat. No.:	HY-107635
CAS No.:	1186372-20-2
Molecular Formula:	$C_{21}H_{14}ClFN_2O_2$
Molecular Weight:	380.8
Target:	Others
Pathway:	Others
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 31.25 mg/mL (82.06 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.6261 mL	13.1303 mL	26.2605 mL
	5 mM	0.5252 mL	2.6261 mL	5.2521 mL
	10 mM	0.2626 mL	1.3130 mL	2.6261 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (5.46 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

TMN355 is a potent chemical cyclophilin A inhibitor and reduces foam cell formation and cytokine secretion. TMN355 is used for atherosclerosis[1].

IC_{50} & Target

cyclophilin A[1]

In Vitro

TMN 355 (0.5-10 μM; 3-9 hours) results in 75.9% reduction of cyclophilin A protein expression. And 1 μM TMN 355 inhibits cyclophilin A after 6 h of activation[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	THP cell lines

Concentration:	0.5, 1, 2.5, 5 and 10 μM
Incubation Time:	3, 6 and 9 hours
Result:	Resulted in 75.9% reduction of cyclophilin A protein expression.

CUSTOMER VALIDATION

- Cell Rep. 2021 Apr 6;35(1):108959.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Ramachandran S, et al. Cyclophilin A enhances macrophage differentiation and lipid uptake in high glucose conditions: a cellular mechanism for accelerated macro vascular disease in diabetes mellitus. Cardiovasc Diabetol. 2016 Nov 3;15(1):152.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA